Beta Bionics, Inc. (BBNX) fair value analysis
Nasdaq · Updated 2026-10-19
BBNX price how computed
Valuation status
No fair-value estimate yetBBNX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BBNX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $16.35
- Sector
- Healthcare
- 12-month range
- $8.86–$31.99
- Market cap
- $882M
- From 52-week high
- -48.9%
- Shares outstanding
- 53.9M
- Rank in Healthcare by quality score
- #96 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Beta Bionics, Inc. is a healthcare company that develops and commercializes automated insulin delivery systems and related diabetes management technologies. The company operates primarily in the United States and serves patients with Type 1 diabetes and insulin-dependent Type 2 diabetes.
BBNX currently ranks #96 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $882M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $119M
- Net margin
- -61.3%
- EPS (TTM)
- $-1.52
- Gross margin
- 59.0%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 311.7%
- Shares outstanding
- 53.9M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 24 · oversold
- 50-day average
- $18.97
- 200-day average
- $15.17
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-27 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+14.5%)
2026-03 ▲ beat (+20.0%)
2025-12 ▲ beat (+21.1%)
2025-09 ▲ beat (+19.5%)
2025-06 ▲ beat (+42.6%)
2025-03 ▼ miss (-82.4%)
2024-12 ▼ miss (-123.6%)
2024-09 ▼ miss
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 4 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $24.2
- Target vs last price
- +48.0%
What our data shows for BBNX
- Shares are trading in the lower third of their 12-month price range of $8.86–$31.99.
- The 14-day relative strength index sits at an oversold 24.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BBNX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BBNX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — BBNX's RSI zone shifted from neutral to oversold this week, indicating that the stock's recent price movement has entered territory associated with potential oversold conditions. The stock remains in the Healthcare sector with a current valuation verdict of awaiting full valuation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BBNX have shifted this week, with the 50/200-day trend state moving from uptrend to mixed. This change reflects evolving price momentum patterns in the healthcare stock. The valuation assessment for BBNX remains incomplete as full valuation data is still being compiled.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BBNX stock undervalued?
TickrTrends has no fair-value estimate for BBNX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BBNX's TickrTrends verdict?
BBNX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BBNX compare to other Healthcare stocks?
BBNX ranks #96 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BBNX overbought or oversold?
BBNX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does BBNX report earnings next?
BBNX's next earnings report is scheduled for 2026-10-27 (post-market), per the published earnings calendar.
Does BBNX usually beat earnings estimates?
Over its last 8 reported quarters BBNX beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BBNX?
Of 13 analysts covering BBNX, 9 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $24.2 (+48.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.